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Abstract: The synthetic peroxides OZ78 and MT04 recently emerged as fasciocidal drug candidates.
However, the effect of iron on fasciocidal activity and hepatocellular toxicity of these compounds is
unknown. We investigated the in vitro fasciocidal activity and hepatocellular toxicity of OZ78 and
MT04 in absence and presence of Fe(II)chloride and hemin, and conducted a toxicological study in
mice. Studies were performed in comparison with the antimalarial artesunate (AS), a semisynthetic
peroxide. Fasciocidal effects of OZ78 and MT04 were confirmed and enhanced by Fe2+ or hemin. In
HepG2 cells, AS reduced cellular ATP and impaired membrane integrity concentration-dependently.
In comparison, OZ78 or MT04 were not toxic at 100 µM and reduced the cellular ATP by 13% and
19%, respectively, but were not membrane-toxic at 500 µM. The addition of Fe2+ or hemin increased
the toxicity of OZ78 and MT04 significantly. AS inhibited complex I, II, and IV of the mitochondrial
electron transport chain, and MT04 impaired complex I and II, whereas OZ78 was not toxic. All
three compounds increased cellular reactive oxygen species (ROS) concentration-dependently, with a
further increase by Fe2+ or hemin. Mice treated orally with up to 800 mg OZ78, or MT04 showed
no relevant hepatotoxicity. In conclusion, we confirmed fasciocidal activity of OZ78 and MT04,
which was increased by Fe2+ or hemin. OZ78 and MT04 were toxic to HepG2 cells, which was
explained by mitochondrial damage associated with ROS generation in the presence of iron. No
relevant hepatotoxicity was observed in mice in vivo, possibly due to limited exposure and/or high
antioxidative hepatic capacity.
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1. Introduction
Fasciola hepatica (F. hepatica) is a food-borne trematode, which infects 2 to 17 million people
worldwide. The parasite settles in the liver, bile ducts, and the gallbladder of the host, causing
fascioliasis. A global burden of about 1.7 million DALYs (disability-adjusted life years) has been
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attributed to the cluster of food-borne trematode infections in 2016 [1–3]. Fascioliasis is not only an
important human health problem but is also of enormous importance in veterinary health [4].
Triclabendazole is the first-choice therapy against fascioliasis. However, resistance to this
anthelmintic drug has been documented globally in veterinary medicine and is threatening treatment
and control of fascioliasis [5].
Artemisinin (see Figure 1 for chemical structure), a natural product from the plant Artemisia
annua, and its derivatives are the most widely used drugs against malaria [6]. The semi-synthetic,
water-soluble derivative artesunate (AS) and its active metabolite α-β-dihydroartemisinin (DHA) are
also active against the liver fluke F. hepatica [7]. In comparison to the semisynthetic artemisinins, fully
synthetic compounds, such as trioxolanes and tetraoxanes [8,9], have a higher bioavailability and
a higher systemic exposure compared to artesunate [10]. For example, OZ78 and MT04 (Figure 1)
exhibited a high trematocidal activity in in vitro and in in vivo models, in parallel to favorable
pharmacokinetic properties [11]. In addition, MT04 showed an egg count reduction by 98.5% and a
worm burden reduction by 92% in sheep naturally infected with F. hepatica, while OZ78 showed no
effect in sheep [12,13].
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Figure 1. Molecular structure of artesunate, OZ78, and MT04.
Different studies have shown that the artemisinins and fully synthetic endoperoxides, such as
trioxolanes and tetraoxanes, react with iron. Free Fe2+ [14,15] or Fe2+ in heme [14,16–18] reduces and
opens the endoperoxide group of these molecules, eventually leading to the formation of C-centered
radicals that can react with different cell constituents, such as heme, phospholipids, proteins, and
DNA [14,17,19]. It has been proposed that heme produced by the degradation of hemoglobin by
malaria parasites is responsible for the activation and therefore, also for the pharmacological activity
of artemisinins and synthetic endoperoxides against malaria [20,21]. Heme–artemisinin adducts have
been isolated from urine and the spleen of parasite-infected mice but not in uninfected mice treated
with artemisinin [22]. Alkylation of heme and of other cell constituents may also be important for the
fasciocidal activity of artemisinins and of synthetic endoperoxides.
The endoperoxide group of the artemisinin-based compounds not only acts as a pharmacophore,
but it has also been shown to be responsible for neuro- and embryotoxicity in rats and rabbits and to
induce mitochondrial dysfunction and apoptosis in HeLa cells [17,23]. Toxic effects were also observed
in F. hepatica infected rats treated with an oral dose of 400 mg/kg AS [7]. However, due to the poor
pharmacokinetic properties of the artemisinins, only low systemic plasma concentrations are reached,
and this might be the reason why there are no reports of neuro- or embryotoxicity in man [24]. OZ78
has no mutagenic potential [8], but, to the best of our knowledge, there is no further data published
about the toxicity of OZ78 and MT04.
In the current study, we had two principal aims. First, we wanted to elucidate the effect of free
Fe2+ and heme-complexed iron on the in vitro fasciocidal activity of the synthetic endoperoxides OZ78
and MT04. Second, taking into account the hepatic localization of liver flukes, we attempted to study
the toxicity of these compounds on HepG2 cells (a human hepatocarcinoma cell line) and on liver
morphology and function of mice in vivo.
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2. Results
2.1. Fe2+ and Hemin Potentiate Fasciocidal Activity of OZ78 and MT04 in Worms Ex Vivo
We have previously shown that OZ78 and MT04 (at 50 µg/mL) have activity against the liver
fluke F. hepatica [25]. In our current work, we investigated temporal effects of OZ78 and MT04 in
combination with Fe2+ or hemin on adult F. hepatica from bovine origin in vitro.
Control worms incubated with 1% DMSO for 72 h did not show a change in viability. In the
presence of iron or hemin for 48 h or 72 h, however, F. hepatica showed a slight reduction in viability
(Figure 2A).
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Figure 2. In vitro activity of artesunate (AS), OZ78, and MT04. Adult F. hepatica were obtained
from bovine livers. Fasciocidal activity was investigated for AS (B), OZ78 (C), and MT04 (D) at a
concentration of 50 µg/mL alone (black line) or in combination with Fe2+ (dashed line) or hemin (dotted
line) and compared to control worms treated with DMSO 1% (A). The limits of the whiskers correspond
to the standard error of the mean values per time point, n = 6.
AS (50 µg/mL) was the most active drug tested in this assay against F. hepatica. All treatments
led to the death of the worms within 72 h (Figur 2B). The combi ation with iron or hemin did not
increase the activity of AS against F. hepatica as compared to treatment with AS alone.
Incubation with OZ78 (50 µg/mL) for 24 h had no effect on worm vitality, whereas incubations
of OZ78 in combination with iron or hemin resulted in a reduction in viability to score 3 (Figure 2C).
Similarly, after 48 h, combined treatment of OZ78 with iron or hemin was more efficient in impairing
worm viability than OZ78 alone. After 72 h, however, we observed that all three treatments reached a
comparable reduction in movements of F. hepatica (score 2).
Worms incubated with MT04 alone were not affected after 24 h. However, after 24 h of coincubation
of MT04 (50 µg/mL) with iron or hemin, liver flukes showed a marked reduction in movement (viability
score of 2.2 or 2.5, respectively, Figure 2D). After 72 h of treatment with MT04 alone or in combination
with iron, we observed reduced viability of F. hepatica (score 1.6), whereas MT04 plus hemin led to the
death of the worms.
Our results confirm that both OZ78 and MT04 are active drugs against F. hepatica and that, in
contrast to AS, Fe2+ or hemin accelerated or enhanced the toxicity of OZ78 or MT04 (with hemin being
more effective than iron).
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2.2. Impact of AS, OZ78 or MT04 on Membrane Integrity and ATP Content of HepG2 Cells
AS has been described in case reports to be hepatotoxic in humans [26–28]. We wanted to
corroborate the effect of AS in a human hepatocarcinoma cell line and to extend our studies on the
new drug candidates OZ78 and MT04. Having shown that iron and hemin augmented the efficacy
of OZ78 and MT04 in worms ex vivo (Figure 2), we included FeCl2 and hemin in our toxicological
studies (Figure 3).
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was used as positive control reflec ing complete cell lysis (7-fo d increase compared to DMSO, data not
shown). (B) Intracellular ATP content expressed relative to DMSO control. Results represent the mean
of five ind pendent exp r ments carried out in triplic tes. Data represent the me n ± STD. Asterisks
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To investigate membrane integrity, we monitored the release of adenylate kinase induced by
the t st compounds alone r in combinatio with Fe2+ or hemin (Figure 3A). Triton X significantly
i cr ased the aden late kin se (AK) releas by a factor of seven c mpared to DMSO control (data not
shown). Due to its brow color, hemin int rfered with the denylate kinase assay (and all other assays
currently available to measure membrane leakage) and co ld not be evaluated.
AS was increasingly toxic at 100 and 500 µM, with an increase in AK release by 190% and 270%,
respectiv ly, as compared to DMSO control. At 100 µM, Fe2+ augmented membrane l akage of AS
(320%), whereas Fe2+ alone was not cytotoxic. High conce trations of AS (500 µM) in the presence of
Fe2+ accelerated cellular impairment as observed by microscopic investigation (lyzed cells, pictures
not shown). However, possibly due to the limited half-life of AK in the supernatant, the significant
decrease in viability did not translate in appropriate levels of active AK.
OZ78 or MT04 did not impair membrane integrity up to 500 µM. While the combined treatment of
MT04 with Fe2+ induced a significant release of AK (200% increase as compared to DMSO), cotreatment
of OZ78 with Fe2+ did not.
We expanded the cytotoxicity experiments by measuring cellular ATP content (Figure 3B), a
non-destructive assay that was not hampered by the hemin solution. Fe2+ and hemin alone had no
impact on cellular ATP content. In the presence of Triton X as a positive control, almost no ATP was
left in cells (data not shown). AS (100 µM) decreased the cellular ATP content by 55% as compared
to DMSO after 24 h of incubation. When AS was coincubated with iron or hemin, ATP dropped by
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93% and 95%, respectively, as compared to control. Five hundred micromolar of AS alone caused a
complete depletion in cellular ATP irrespective of the presence of iron or hemin.
OZ78 (100 µM) alone or in combination with Fe2+ was not toxic. In contrast, cotreatment of OZ78
with hemin triggered a slight, but significant drop in ATP (12%). At 500 µM, OZ78 alone showed a
minor toxic effect (14% decrease in ATP), which was not enhanced by the addition of iron or hemin.
MT04 at 100 µM was not toxic for HepG2 cells. However, in combination with iron or hemin,
a drop in the ATP content by 20% or 40%, respectively, was detected. High concentrations of MT04
(500 µM) decreased intracellular ATP by 20%. Coincubations with iron or hemin triggered an additional
loss in ATP, resulting in an overall decrease of 65%.
The results show that AS was more toxic than the two synthetic peroxides under investigation,
with MT04 being more toxic than OZ78 in HepG2 cells. The presence of iron or hemin augmented the
cytotoxic effect induced by AS, OZ78, and MT04.
2.3. AS and MT04 Inhibit Mitochondrial Respiration
In hepatocytes, the main production of ATP occurs in the mitochondria through oxidative
phosphorylation. Having observed a significant drop in cellular ATP levels, we intended to investigate
the effect AS 100 µM, MT04 500 µM, and OZ78 500 µM on mitochondrial respiration in HepG2 cells
(Figure 4).
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Figure 4. AS and MT04 inhibit different complexes of the mitochondrial respiratory chain. HepG2
cells were treated with AS (100 µM), OZ78 (500 µM) or MT04 (500 µM). After 24 hours, cells were
permeabilized with digitonin, and oxygen consumption was measured using the K2 oxygraph
(Oroboros). ADP-stimulated respiration rates were compared in the three groups using glutamate
(+ malate), succinate (+ rotenone) or N,N,N′,N′-tetramethyl-p-phenylendiamine (TMPD) and ascorbate
(+ antimycin) as substrates. Results represent the mean of three independent experiments carried out
in triplicates. Data represent the mean ± SEM. Asterisks indicate significance compared to DMSO
control, * p < 0.05, ** p < 0.01.
Using glutamate and malate as substrates, which produce nicotinamide adenine dinucleotide
(NADH) that enters the electron transport chain at complex I, significant inhibition of the maximal
ADP-stimulated respiration rate was observed for AS and MT04 treated cells (inhibition of 75% and
53%, respectively) as compared to DMSO.
Using succinate (and rotenone to inhibit complex I) as substrate, which produces flavin adenine
dinucleotide (FADH) that enters the electron transport chain at complex II, we again detected significant
differences among AS and MT04 treated cells compared to the control. AS inhibited mitochondrial
respiration by 83%, whereas MT04 inhibited succinate metabolism by 61% compared to control.
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In the presence of N,N,N′,N′-tetramethyl-p-phenylendiamine (TMPD)/ascorbate (and antimycin
A to inhibit complex III), which was used to investigate the activity of complex IV, the maximal
ADP-stimulated respiration rate was decreased by AS by 47%, whereas MT04 inhibited mitochondrial
respiration of HepG2 cells by 22% without reaching statistical significance.
For comparison, OZ78 inhibited mitochondrial oxidative metabolism in the presence of succinate
or ascorbate/TMPD only numerically, but without reaching statistical significance.
2.4. Effect of AS, OZ78 or MT04 on ROS Accumulation
Impairment of mitochondrial respiration has been associated with the generation of reactive oxygen
species (ROS) [29]. Moreover, the generation of radicals in the presence of iron or hemin is a widely
accepted explanation of why artemisinins are toxic to parasites and mammalian cells [10,17,19,30].
Therefore, we determined the ROS concentration in HepG2 cells after 90 min and 24 h treatment with
AS, OZ78, or MT04 alone or in the presence of iron or hemin (Figure 5).
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Figure 5. Effect of Fe2+ and hemin on cellular generation of reactive oxygen species (ROS). HepG2
cells were treated with AS, OZ78 or MT04 (100 or 500 µM) alone or in the presence of Fe2+ or hemin.
ROS abundance was measured using dichlorodihydrofluorescein diacetate (DCF-DA) after 90 min and
24 h. Results are expressed as mean ± STD of four independent experiments carried out in triplicates.
*p < 0.05 vs. control incubation containing DMSO, DMSO + Fe2+ or DMSO + hemin. +p < 0.05 versus
the respective incubation containing only the investigated compound but no addition (Fe2+ or hemin).
The solvent control, DMSO, and Fe2+ did not trigger ROS production within 90 min or 24 h
incubation, whereas hemin induced a significant increase in ROS by a factor of 10 after 90 min or of
30 after 24 h compared to DMSO. In the absence of exogenous iron, none of the compounds investigated
increased the cellular ROS after 90 min, but AS and OZ78 increased the cellular ROS content after 24 h
by a factor of 5. After an incubation of 90 min, the addition of Fe2+ to the compounds investigated
did not increase the ROS content. In contrast, the addition of hemin significantly increased the ROS
content after 90 min for all compounds investigated compared to respective incubations containing
only hemin. After 24 h, the addition of Fe2+ increased the cellular ROS content for AS and OZ78, but
not for MT04. In comparison, the addition of hemin increased the ROS content for all compounds
investigated compared to the respective incubations containing only hemin.
2.5. No Significant Metabolism of OZ78 and MT04 by Human Liver Microsomes
It has been reported that AS is extensively metabolized in the liver, inhibits several cytochrome
P450 is forms (CYPs) and aut -induces its own metabolism [31]. For OZ78 and MT04, no data exist
regarding their stability in the presence of CYPs. We, therefore, tested the decay of AS, OZ78 or MT04
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by measuring the concentration of the respective parent substance after 2 hours of incubation in the
presence of functional or heat-inactivated microsomes. We confirmed the rapid and almost complete
metabolism of AS after 2 hours of incubation with functional microsomes (94% of AS was metabolized).
In contrast, in the presence of heat-inactivated microsomes, no degradation was detected. OZ78 and
MT04 did not show a decrease in the presence of functional microsomes, indicating that OZ78 and
MT04 are not or very slowly metabolized by CYPs.
2.6. No Significant Liver Toxicity of OZ78 and MT04 in Mice
In previous studies, we have shown that oral application of a single dose of AS (200 mg/kg), OZ78
(100 mg/kg) or MT04 (50 mg/kg) to rats infected with F. hepatica efficiently killed juvenile and adult
liver flukes in vivo [25,32]. In the present study, we focused on potential hepatic adverse effects of
AS, OZ78, and MT04 in mice. As AS was found to be the most toxic compound tested in our in vitro
toxicity tests in HepG2 cells, we performed a pilot-study treating mice with a single oral dose of
400 mg/kg AS. We analyzed plasma aspartate aminotransferase (AST), alkaline phosphatase (aPhos),
and total serum bilirubin after 2, 4, 8, 12, 24 h. Mice were sacrificed after 24 h, and liver biopsies were
investigated. Highest values for all clinical parameters tested were obtained at 8 h, and no liver lesions
were observed after 24 h (data not shown).
Based on these results, we investigated the effects of increasing doses of AS, OZ78 or MT04
(200–800 mg/kg) in mice 8 hours post-treatment (Figure 6). In the group of AS treated mice, we found
that doses of 200 and 400 mg/kg were not associated with liver injury. At 800 mg/kg, one mouse was
without lesions, one with steatosis, and one with confluent necrosis (Supplementary Table S1). While
aPhos and bilirubin did not increase in the group of AS treated mice, AST moderately increased with
escalating doses of AS, compatible with hepatocyte necrosis found in liver histology (Figure 6).
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bilirubin were analyzed in plasma from mice treated with single doses of 200, 400, and 800 mg/kg of 
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Figure 6. Effect of AS, OZ78, and MT04 on the activity of aspartate aminotransferase (AST) and alkaline
phosphatase (aPhos) and on the serum bilirubin concentration. AST, aPhos, and total serum bilirubin
were analyzed in plasma from mice treated with single doses of 200, 400, and 800 mg/kg of AS, OZ78 or
MT04 or vehicle control (DMSO). Blood was obtained 8 hours after oral administration. Each data point
in the graph corresponds to one mouse. The mean of each group is indicated. *p < 0.05 vs. respective
control group (DMSO).
In all three groups of mice treated with OZ78, we observed two mice (out of four) with
slight hydropic degeneration of hepatocytes (Supplementary Table S1). Hydropic degeneration
or swelling usually results from non-specific cell injury, leading to water accumulation and is reversible.
Alternatively, it may also occur during sample preparation. The three clinical parameters investigated
(AST, total bilirubin, and aPhos) were in the normal range (Figure 6).
Mice treated with 200 or 400 mg/kg MT04 also showed no pathologic liver histology (Supplementary
Table S1). Three out of four mice treated with 800 mg/kg MT04 presented hydropic degeneration.
One of these mice had a concomitant elevation of AST. Importantly, we observed a similarly elevated
AST activity for a mouse without hydropic degeneration, suggesting that hydropic degeneration
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was not necessarily associated with hepatocellular damage and may have been an artifact occurring
during sample preparation. One mouse with hydropic degeneration had an increased total bilirubin
plasma concentration, whereas the other two mice with hydropic degeneration had normal plasma
bilirubin values. Two mice treated with 200 mg/kg MT04 had highly elevated AST values, however,
without underlying liver pathology. With increasing doses of MT04, we did not observe a concomitant
rise in AST (Figure 6), indicating that, in contrast to AS, MT04 did not affect AST levels in a
concentration-dependent fashion.
3. Discussion
Fascioliasis is a major public health and veterinary problem [33]. Resistance to the only available
drug triclabendazole is a big motivation to search for new drugs [34,35]. OZ78 and MT04 have been
shown to be effective against fascioliasis [25]. However, there is currently no data available regarding
toxicity, and there are knowledge gaps in the mechanism of action.
Our results confirm that both OZ78 and MT04 are active against F. hepatica and that the addition
of iron, in particular in the form of hemin, enhances both trematocidal activity and toxicity of OZ78
and MT04 (Figure 2). This finding is in line with previous in vitro studies demonstrating augmented
tegumental changes caused by OZ78 in the presence of hemin [36]. In addition, in vivo studies
demonstrated that nonperoxidic OZ derivatives lack fasciocidal activity in the rat model, strongly
supporting a peroxide-bond-dependent mechanism of action against liver flukes [37].
It has been reported that AS is extensively metabolized in the liver, inhibits several cytochrome
P450 isoforms (CYPs) and auto-induces its own metabolism [27]. For OZ78 and MT04, no data exist
regarding their stability in the presence of CYPs. We, therefore, tested the decay of AS, OZ78 or MT04
in the presence of functional human liver microsomes (hLM) and confirmed the rapid and almost
complete degradation of AS. This observation is in line with studies performed in the presence of rat
or human microsomes as well as recombinant CYP450s (rCYPs). Previous studies demonstrated that
AS is metabolized by CYP2A6, predicting hepatic metabolism and also the potential for drug–drug
interactions in vivo [31,38]. In contrast to AS, we did not observe microsomal degradation of OZ78
and MT04 in vitro, suggesting that hepatic metabolism is not necessary for the trematocidal activity of
OZ78 and MT04 and that OZ78 and MT04 carry a low risk for drug–drug interactions.
AS has been described in case reports to be hepatotoxic in humans [26–28]. The fully synthetic
compounds under investigation, OZ78 and MT04, are chemically related peroxides and could also be
hepatotoxic, even if they are not metabolized by CYPs. We aimed to investigate whether OZ78 and
MT04 reveal hepatocellular toxicity at the concentrations required for fasciocidal activity (100–500 µM).
The investigations were also carried out in the presence of two iron compounds, Fe2+ and hemin.
Peroxide bond cleavage induced by iron, resulting in radical formation, is not only a proposed
mechanism of action but could also be associated with toxicity [10,17,30]. The antimalarial drug AS
served as a comparator.
We applied two assays to assess cell viability and metabolic toxicity. For that, we chose the AK
release assay to measure membrane leakage and the CellTiter Glo assay to assess the cellular ATP
content. OZ78 and MT04, at both concentrations tested, did not result in a significant loss in membrane
integrity in HepG2 cells. In the presence of Fe2+, OZ78 did not result in membrane leakage, but MT04
was slightly toxic. For comparison, the effect on the cellular ATP content was more pronounced for
both compounds. OZ78 decreased the cellular ATP content at 500 µM irrespective of the presence of
iron or hemin, and MT04 reduced the cellular ATP content to an even greater extent. The higher toxicity
of MT04 compared to OZ78 might be explained by the fact that MT04 contains two peroxide bridges
as compared to one for OZ78 (Figure 1). AS was the most toxic drug tested. AS showed significant
cellular toxicity, in particular in combination with iron, as indicated by AK release and decrease in the
cellular ATP content. The in vitro toxicity findings are in line with recent studies, which have shown
the occurrence of apoptotic processes in the presence of ferrous salts of the artemisinins on rapidly
proliferating cells [30,39].
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The observation that the drugs investigated had a more pronounced effect on the cellular ATP
content than on membrane integrity (Figure 3) prompted us to assume mitochondrial toxicity and to
study the action of the compounds on mitochondria in more detail. As shown in Figure 4, AS inhibited
TMPD/ascorbate-mediated oxygen consumption by HepG2 cells, indicating that AS is a complex IV
inhibitor. In addition, it impaired glutamate/malate- and succinate-mediated oxygen consumption,
compatible with inhibition of complex I and II. Similarly, MT04 inhibited glutamate/malate- and
succinate-mediated oxygen consumption, but without inhibiting complex IV. In contrast, OZ78 did
not significantly impair mitochondrial function. These data correlate well with ATP depletion in
the absence of Fe2+ or hemin (Figure 3B). Mitochondrial toxicity may be a consequence of increased
cellular ROS levels, which may first increase due to the formation of radicals from the endoperoxides
investigated and then also due to the dysfunction of the mitochondrial electron transport chain [17,29].
In support of this assumption, all three compounds investigated were associated with an increase in the
cellular ROS content and the addition of iron not only increased ROS formation but also cytotoxicity.
Compatible with impairment of respiratory chain complexes, ATP depletion and AK release
induced by AS in cellular assays, we demonstrated that a single high dose of AS gave rise to slightly
increased AST levels and concomitant hepatocyte necrosis/steatosis in vivo. Published LD50 values
of AS in mice were 520 and 475 mg/kg after single intravenous and intramuscular administration,
respectively [12]. In our study, we administered up to 800 mg/kg orally with moderate toxicity,
indicating that the oral bioavailability in mice was limited. In contrast to AS, we detected no relevant
hepatic toxicity for OZ78 or MT04 in vivo, despite the demonstration of clear in vitro toxicity at least
for MT04. A possible explanation for this apparent discrepancy is limited exposure. Since we did not
measure plasma or liver concentrations, we do not know whether the toxic concentrations were reached
in the mice treated with these compounds. It is also possible that the generation of mitochondrial
damage needs more time than the eight hours chosen in the current study. Furthermore, the liver has a
high antioxidative capacity, which may have suppressed ROS accumulation.
Since resistance is a problem in the treatment of fascioliasis [5], drug combinations could also
be investigated. Considering the possible combination of endoperoxides, we would expect additive
effects for fasciocidal activity and toxicity, since the pharmacophores, which are also the toxophores,
are similar. Regarding the prevention of resistance, a combination could possibly be beneficial if the
mechanism of resistance did not involve the active center of the drugs. Future in vitro and in vivo
studies should be conducted to investigate this question.
4. Materials and Methods
4.1. Materials
MT04 and OZ78 were kindly supplied by the College of Pharmacy, University of Nebraska
Medical Centre (Omaha, NE, USA, [40]). AS was obtained from Mepha AG (Aesch, Switzerland) and
DHA was kindly provided by Dafra Pharma (Turnhout, Belgium). Chemical structures are shown in
Figure 1. Triton-X-100 (Sigma–Aldrich, Switzerland) was used as a positive control to induce full cell
lysis. Cell culture plates were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Human liver
microsomes were purchased from BD Gentest (Woburn, MA, USA). All other chemicals used were
ordered from Sigma or Fluka.
4.2. Metabolism in the Presence of Human Liver Microsomes
The metabolism of AS, MT04, and OZ78 was tested in the presence of human liver microsomes or
heat-inactivated microsomes (70 ◦C for 20 min, referred to as control microsomes) at 37 ◦C. AS, MT04 or
OZ78 (10 µM each) were added to 1.0 mL of reaction mixture consisting of microsomes (0.5 mg/kg), an
NADPH regenerating system, and PBS buffer, pH 7.4. Adding the drugs started the reaction. Aliquots
of 100 µL were transferred into Eppendorf tubes after 0, 15, 30, 60, 120 min. The reaction was stopped
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by adding 300 µL methanol. The samples were then vortexed and centrifuged at 3000 g for 30 min.
Supernatants were taken for LC-MS analysis.
4.3. LC-MS/MS Analysis
LC-MS/MS measurements for AS were performed as described recently [41]. Briefly, sample
measurements were done with a high-performance liquid chromatography (HPLC) system (Shimadzu,
Kyoto, Japan) connected to an API 365 triple-quadrupole mass spectrometer (PE Biosystems, Foster
City, CA, USA) with a turbo ion spray interface. AS was detected in positive ionization mode by
selected reaction monitoring (SRM) with a transition of 267.4→163.0. For analyte separation, a reversed
phase column was used (2.1 × 10 mm guard cartridge (3 µm) connected to a 2.1 × 20 mm Atlantis T3
3 µm analytical column (Waters, Milford, MA, USA)). A gradient was used (mobile phase A: 5 mM
ammonium formiate plus 0.15% (v/v) formic acid in ultra-pure water, mobile phase B: 0.15% (v/v) formic
acid in acetonitrile) at a flow rate of 0.3 mL/min.
The analysis of MT04 and OZ78 [42] was conducted using the same system as described for AS.
A phenomenex C8 (50 mm × 2.00 mm, 5 µm, Brechbühler AG, Schlieren, Switzerland) was used for
chromatographic separation with a gradient (mobile A: 5 mM ammonium formiate in water and mobile
B: acetonitrile) at a flow rate of 0.3 mL/min. MS was conducted in negative ionization mode. For OZ78
and MT04 a mass of 321.4 and 337.4, respectively, was detected.
4.4. In Vitro/Ex Vivo Worm Studies
The experiments were performed, as described previously [43]. Adult F. hepatica were collected
from bovine liver bile ducts obtained from the local slaughterhouse (Basel, Switzerland). After careful
washing, a single adult worm was placed per well (6-well plate, Costar, MA, USA) containing 5.4 mL
RPMI 1640 (Gibco, N.Y., USA), supplemented with 1% (v/v) antibiotics (50 µg/mL streptomycin and
50 U/mL penicillin), 1% (v/v) drug solution, and 8% (v/v) hemin or FeCl2 solution. Adult F. hepatica
were incubated in the presence of 50 µg/mL AS, MT04 or OZ78 combined with either FeCl2 solution or
hemin. Control worms were incubated in 1% (v/v) DMSO combined with iron or hemin. Experiments
were conducted in triplicates and repeated once. Cultures were kept at 37 ◦C in an atmosphere of 5%
CO2. The viabilities of treated and untreated worms were monitored at 0, 24, 48, and 72 h. Worms were
examined by eye and/or using a dissecting microscope (20× lenses). The viability of adult flukes was
scored using the following scale: 4: normal activity; movements were visible without a microscope,
3: reduced activities, 2: very weak activities detected only using microscopic magnification, and
1: death of worm (no movement observed for two min using a microscope).
4.5. Cell Culture Conditions
The human hepatocarcinoma cell line HepG2 was purchased from ATCC (Manassas, Virginia,
USA). HepG2 cells were maintained in DMEM containing 1 g/L glucose supplemented with 10%
fetal bovine serum, 5% non-essential amino acids, and HEPES buffer, pH 7.2 (Invitrogen, Reinach,
Switzerland). Cells were incubated under humidified air containing 5% CO2 at 37 ◦C. For cell counting,
cells were trypsinized for 5 min until they were detached, stained with trypan blue and then counted
using a hemocytometer. Cells were seeded at a density of 20,000 cells/96 well.
4.6. Treatment of HepG2 Cells
Stock solutions of the drugs tested were prepared in DMSO 100% (v/v). Final concentrations of
DMSO did not exceed 0.1% (v/v) for all experiments performed. Drug solutions of OZ78 and MT04
in medium tend to precipitate and were, therefore, prepared two days in advance and incubated at
room temperature in the dark to ensure complete dissolution. LC-MS measurements confirmed the
stability of the compounds (data not shown). Treatments with AS, MT04, or OZ78 (100 or 500 µM) were
performed either alone or in combination with 8% (v/v) hemin or FeCl2 solution for 24 h. The final iron
concentration used was 122 µM (stock 1.5 mM) based on previous in vitro studies with F. hepatica [36].
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The hemin solution was prepared as follows: 5 mg hemin was dissolved in 1 mL of 0.1 M aqueous
NaOH, 3.95 ml of PBS (pH = 7.4) and 0.05 ml of 1 M HCl was added to adjust the pH to 7.1–7.4 [36].
For the iron-solution, a hydrated salt was used and solved in ultra-pure water. All solutions were
sterile filtered (0.2 µm) after preparation.
In viability assays, HepG2 cells were treated with 0.1% Triton-X or 0.1% DMSO for positive or
negative control, respectively.
4.7. Adenylate Kinase Leakage (Membrane Integrity Test)
The ToxiLight® BioAssay Kit LT007-117 was obtained from Lonza (Basel, Switzerland). The assay
was used according to the protocol supplied by the manufacturer. Adenylate kinase (AK) release was
used to assess cell membrane integrity and was determined 24 h after treatment with AS, MT04 or
OZ78 with or without the combination of Fe2+ or hemin.
4.8. ATP Content
To assess cellular ATP content, HepG2 cells were seeded in white-wall 96-well plates with a clear
bottom (Nunc). One day after seeding, cells were treated with the respective drugs. After 24 h of
treatment, the medium was removed, and the cells carefully washed with PBS containing Ca2+/Mg2+
(0.1 g/L each) to remove all hemin. Finally, 50 µl PBS was added to each well and incubated with
50 µL CellTiter-Glo reagent as described in the protocol provided by the manufacturer (Promega).
Luminescence was measured using Tecan M200 Infinite Pro.
4.9. High-Resolution Respirometry
After incubation with different drugs for 24 h, HepG2 cells were trypsinized and resuspended
in DMEM with 10% fetal calf serum (FCS) and then centrifuged for 5 min (180× g). Cells were
resuspended in MiRo5 respiration buffer (110 mM sucrose, 0.5 mM ethylene glycol-bis(β-aminoethyl
ether)-N,N,N′,N′-tetraacetic acid (EGTA), 3.0 mM MgCl2, 80 mM KCl, 60 mM K-lactobionate, 10 mM
KH2PO4, 20 mM taurine, 20 mM Hepes, 1.0 g/L BSA, pH 7.1). Respiration rates were measured at
37 ◦C using a high-resolution oxygraph (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria).
Respiration rates were calculated as the time derivative of oxygen concentration measured in the closed
respirometer. The amplified signal was recorded in a computer with an online display of the calibrated
oxygen concentration and oxygen flux (DatLab software for data acquisition and analysis; Oroboros
Instruments). The mitochondrial complex activity was assessed by a standard titration protocol: first
cells were permeabilized with digitonin (10 µg/1 million cells) for 5 min. Afterward, for complex
I-dependent maximal respiration stimulation, substrates added were glutamate (10 mM) and malate (5
mM), which provide nicotinamide adenine dinucleotide (NADH) to the respiratory chain (complex
I activation), followed by addition of ADP (2.5 mM) (state 3, maximal respiration). After a stable
signal was reached and marked, rotenone (0.5 µM) was added to inhibit complex I, and then complex
II-dependent respiration was stimulated by adding succinate (10 mM), which provides flavin adenine
dinucleotide (FADH) to the respiratory chain (complex II activation, state 3). Afterward, complex
III was inhibited by antimycin A (2.5 µM), and complex IV-dependent respiration was measured
by adding ascorbate (2 mM) and N,N,N′,N′-tetramethyl-p-phenylendiamine (TMPD, 0.5 mM). We
confirmed the integrity of the outer mitochondrial membrane by showing the absence of a stimulatory
effect of exogenous cytochrome c (10 µM) on respiration [44]. Respiration was expressed as oxygen
consumption per 5 × 105 cells.
4.10. Measurement of Reactive Oxygen Species (ROS)
Dichlorodihydrofluorescein diacetate (DCF-DA) dissolved in DMSO was used to assess cellular
formation of reactive oxygen species (ROS). HepG2 cells were seeded in a black-wall 96 well plate with
a clear bottom as described above. Briefly, 30 min before treatment started, DCF-DA was added to the
cells at a final concentration of 25 µM. DCF-DA was removed completely before the drugs were added.
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ROS was measured after 90 min and 24 h of drug exposure using a Tecan M200 Infinite Pro (excitation
485 nm, emission 535 nm).
4.11. In Vivo Studies
All animal studies were carried out at the Swiss Tropical and Public Health Institute (Basel,
Switzerland) and were approved by Swiss and cantonal authorities (permission: 2070). Female
NMRI mice (age: 3–4 weeks, weight: ~20 g) were purchased from Harlan Laboratories (Horst, The
Netherlands). Mice were kept in groups of 10 animals in macrolon-cages in environmentally controlled
conditions (temperature: ~25 ◦C; humidity: ~70%; 12 h light/dark cycle) and acclimatized for one
week. They had free access to water and rodent diet. For the in vivo studies AS, OZ78 or MT04 were
suspended in 7% (v/v) Tween-80 and 3% (v/v) ethanol.
Since treatment of F. hepatica infections in animals is typically performed by a single oral dose [11,45],
we performed a pilot study to find out the best time point to kill the mice at which we could observe
hepatic toxicity after drug application. This time point was 8 h after drug application (data not shown).
In the final experiment, mice were treated with 200, 400, or 800 mg/kg AS, OZ78, or MT04 by oral
gavage. Seven mice were left untreated for control measurements. According to the results of the
pilot experiments, where we measured the highest increase in total serum bilirubin, AST or alkaline
phosphatase 8 h post-treatment, mice were euthanized by CO2 8 h post-treatment, blood was collected
and analyzed as described above. After blood collection, the liver was removed, carefully examined
macroscopically, and gross lesions were recorded. Livers were then stored in formalin 10% (v/v) until
fixation in 4% paraformaldehyde was performed. After embedding in paraffin, sections of 5 µm
thickness were obtained, stained with hematoxylin and eosin, and examined using light microscopy.
4.12. Statistical Analysis
Results were expressed either as mean ± standard deviation or as mean ± standard error of the
mean, as indicated in the figure legends. Means were compared using analysis of variance followed by
the Newman–Keuls test to localize differences.
5. Conclusions
MT04 and OZ78 have trematocidal activity, which is more pronounced in the presence of iron.
Both OZ78 and MT04 are cytotoxic on HepG2 cells, a finding explained best by mitochondrial toxicity
due to ROS accumulation. Toxicity and ROS accumulation were enhanced by iron. In mice, single doses
of MT04 and OZ78 up to 800 mg/kg were without relevant toxicity, suggesting that these compounds
may have a large therapeutic window. Further studies, in particular, long-term administration in
healthy and infected animals, are important for estimating the toxicological potential of these new
trematocidal compounds.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/19/
4880/s1.
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